Sugi Predict

Sugi Predict / Compounds / SCHEMBL10140280

SCHEMBL10140280

SCHEMBL10140280

NCCNC(=O)CCCCCNC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.74
▸ CA12 O43570 3/20 0.62
▸ CA1 P00915 3/20 0.62
▸ CA2 P00918 3/20 0.62
▸ CA9 Q16790 3/20 0.62
▸ MEN1 O00255 1/20 0.61
▸ ABL1 P00519 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ IDE P14735 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ RIN1 Q13671 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ PLCD1 P51178 1/20 0.60
▸ ITGB1 P05556 1/20 0.57
▸ ITGA4 P13612 1/20 0.57
▸ HLCS P50747 1/20 0.57
▸ F2 P00734 1/20 0.57
▸ PRSS1 P07477 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3072383 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
Ethylenediamine SCHEMBL565340 0.99 TDP1 (0.73) TDP1CA12CA1CA2CA9
SCHEMBL26598596 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL15895090 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL30821562 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL25014977 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL24420141 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL10000338 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL3256514 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL10140274 0.97 TDP1 (0.72) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 — — EP claimed
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2025-09-18 — — US disclosed
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 — — EP disclosed
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 — — EP disclosed
US-11517529-B2 Orally bioavailable lipid-based constructs SDG, INC. (US) 2022-12-06 — — US disclosed
US-11517529-B2 Orally bioavailable lipid-based constructs SDG, INC. (US) 2022-12-06 — — US disclosed
EP-3391876-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2021-03-10 — — EP disclosed
EP-3391876-B1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG INC (US) 2021-03-10 — — EP disclosed
US-20200405638-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG INC (US) 2020-12-31 — — US disclosed
US-20100247625-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-09-30 — — US disclosed
US-20100247625-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-09-30 — — US disclosed
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, INC. 2010-05-27 — — US disclosed
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, INC. 2010-05-27 — — US disclosed
US-20100080773-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-04-01 — — US disclosed
US-20100080773-A1 Orally Bioavailable Lipid-Based Constructs SDG, INC. 2010-04-01 — — US disclosed
US-20090087479-A1 Orally bioavailable lipid-based constructs SDG, INC. ( AN OHIO CORPORATION) (US) 2009-04-02 — — US disclosed
US-20090087479-A1 Orally bioavailable lipid-based constructs SDG, INC. ( AN OHIO CORPORATION) (US) 2009-04-02 — — US disclosed
US-20070218117-A1 Supra molecular construct for delivery of interferon to a mammal SDG, INC. 2007-09-20 — — US disclosed
US-20070218117-A1 Supra molecular construct for delivery of interferon to a mammal SDG, INC. 2007-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070218117-A1 Supra molecular construct for delivery of interferon to a mammal HAVCR2, IFNAR1, MSR1 TDP1 4728/4885CA12 3516/4885CA1 4190/4885
US-20100080773-A1 Orally Bioavailable Lipid-Based Constructs FABP2, FABP1, LIPC TDP1 4742/4885CA12 3441/4885CA1 2920/4885
US-20100129428-A1 SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL HAVCR2, IFNAR1, IFNG TDP1 4713/4885CA12 3345/4885CA1 4092/4885
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, FABP6 TDP1 4819/4885CA12 3452/4885CA1 2966/4885
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, SGMS2 TDP1 4755/4885CA12 3221/4885CA1 3267/4885
US-11517529-B2 Orally bioavailable lipid-based constructs FABP2, FABP1, FABP6 TDP1 4819/4885CA12 3452/4885CA1 2966/4885
US-20200405638-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, FABP6 TDP1 4819/4885CA12 3452/4885CA1 2966/4885
US-20090087479-A1 Orally bioavailable lipid-based constructs FABP2, FABP1, FABP6 TDP1 4757/4885CA12 2422/4885CA1 2202/4885
US-20100247625-A1 Orally Bioavailable Lipid-Based Constructs FABP2, LIPC, FABP6 TDP1 4650/4885CA12 1226/4885CA1 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.